Research

Hormonal

Utilization of newer non-insulin glucose-lowering drugs (SGLT2 inhibitors and GLP-1RAs) has increased significantly in Australia, driven by cardiovascular and renal benefits, while older agents (sulphonylureas, glitazones) have declined.

If you have Type 2 Diabetes, talk to your doctor about newer medications like SGLT2 inhibitors or GLP-1RAs. These drugs not only lower blood sugar but also protect your heart and kidneys. While they are more expensive than older medications, they are increasingly recommended as first-line treatments due to these additional benefits.

GoodSupportsHIGH confidence
The biggest change was in sodium-glucose cotransporter-2 (SGLT2) inhibitors, for which there was an average annual increase in utilization of 59.4%... followed by glucagon-like peptide-1 receptor agonists (GLP-1RAs), which showed an increase of 31.4%... In contrast, sulphonylurea, glitazone and acarbose utilization declined.
Peter S. Hamblin et al. · Diabetes Obesity and Metabolism · 2024

Why this rating

Large administrative dataset (118 million prescriptions) with robust statistical analysis.

Source

Utilization and cost of non‐insulin glucose‐lowering drugs in Australia from 2013 to 2023

Peter S. Hamblin et al. · Diabetes Obesity and Metabolism · 2024

DOI 10.1111/dom.15893

cohort · n=118727494Cited 6×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →